Advanced

Enteric-coated mycophenolate sodium could be an alternative to methotrexate for GVHD prophylaxis.

Lazarevic, Vladimir LU (2016) In European Journal of Haematology 97(3). p.213-214
Abstract
Morbidity and mortality resulting from acute and subsequently chronic graft-versus-host disease (GVHD) pose a serious challenge to wider applicability of allogeneic stem cell transplantation (SCT). Mycophenolate mofetil (MMF) is a widely used drug in combination with a calcineurin inhibitor and often cyclosporine (CsA), in preventing GVHD. The use of MMF for acute GVHD (aGVHD) prophylaxis appears to result in significantly faster platelet engraftment and a lower incidence of severe mucositis compared to methotrexate, which could reduce the length of hospital stay. However, there is no statistically significant difference between MMF and methotrexate in regards to relapse risk, non-relapse mortality, or overall survival(1) . This article is... (More)
Morbidity and mortality resulting from acute and subsequently chronic graft-versus-host disease (GVHD) pose a serious challenge to wider applicability of allogeneic stem cell transplantation (SCT). Mycophenolate mofetil (MMF) is a widely used drug in combination with a calcineurin inhibitor and often cyclosporine (CsA), in preventing GVHD. The use of MMF for acute GVHD (aGVHD) prophylaxis appears to result in significantly faster platelet engraftment and a lower incidence of severe mucositis compared to methotrexate, which could reduce the length of hospital stay. However, there is no statistically significant difference between MMF and methotrexate in regards to relapse risk, non-relapse mortality, or overall survival(1) . This article is protected by copyright. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Haematology
volume
97
issue
3
pages
213 - 214
publisher
Wiley-Blackwell
external identifiers
  • pmid:26712567
  • scopus:84982131038
  • wos:000383470200001
ISSN
1600-0609
DOI
10.1111/ejh.12727
language
English
LU publication?
yes
id
fa362915-6a5b-4030-b632-7d733b81e1ae (old id 8500274)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26712567?dopt=Abstract
date added to LUP
2016-01-06 20:11:11
date last changed
2017-09-18 11:29:05
@misc{fa362915-6a5b-4030-b632-7d733b81e1ae,
  abstract     = {Morbidity and mortality resulting from acute and subsequently chronic graft-versus-host disease (GVHD) pose a serious challenge to wider applicability of allogeneic stem cell transplantation (SCT). Mycophenolate mofetil (MMF) is a widely used drug in combination with a calcineurin inhibitor and often cyclosporine (CsA), in preventing GVHD. The use of MMF for acute GVHD (aGVHD) prophylaxis appears to result in significantly faster platelet engraftment and a lower incidence of severe mucositis compared to methotrexate, which could reduce the length of hospital stay. However, there is no statistically significant difference between MMF and methotrexate in regards to relapse risk, non-relapse mortality, or overall survival(1) . This article is protected by copyright. All rights reserved.},
  author       = {Lazarevic, Vladimir},
  issn         = {1600-0609},
  language     = {eng},
  number       = {3},
  pages        = {213--214},
  publisher    = {Wiley-Blackwell},
  series       = {European Journal of Haematology},
  title        = {Enteric-coated mycophenolate sodium could be an alternative to methotrexate for GVHD prophylaxis.},
  url          = {http://dx.doi.org/10.1111/ejh.12727},
  volume       = {97},
  year         = {2016},
}